StockData
Standard BioTools Inc. logo

Standard BioTools Inc. (LAB) stock

LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.65+0.01 (+1.31%)

Close on Nov 12, 2026Market cap $255.73MP/E 3.0Yield –

Standard BioTools price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Standard BioTools's price to sales ratio was 3.0× on Nov 11, 2026, against 6.7× a year earlier. Over the last 5 years it ranged from 0.8× to 7.4×, with a median of 3.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.0×−2.7
2025Dec 31, 20255.7×+0.2
2024Dec 31, 20245.5×+3.8
2023Dec 29, 20231.7×+0.8
2022Dec 30, 20220.8×−1.3
2021Dec 31, 20212.2×−1.3
2020Dec 31, 20203.5×+1.5
2019Dec 31, 20192.1×−1.1
2018Dec 31, 20183.1×+0.8
2017Dec 29, 20172.3×+0.4
2016Dec 30, 20161.9×−0.7
2015Dec 31, 20152.6×−6.5
2014Dec 31, 20149.2×−5.7
2013Dec 31, 201314.9×+7.7
2012Dec 31, 20127.2×+0.6
2011Dec 30, 20116.6×–

More Standard BioTools figures

See a number that looks wrong?